Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

2.

Peripheral nervous system insulin resistance in ob/ob mice.

Grote CW, Groover AL, Ryals JM, Geiger PC, Feldman EL, Wright DE.

Acta Neuropathol Commun. 2013 May 10;1:15. doi: 10.1186/2051-5960-1-15.

3.

Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice.

Groover AL, Ryals JM, Guilford BL, Wilson NM, Christianson JA, Wright DE.

Pain. 2013 Dec;154(12):2658-67. doi: 10.1016/j.pain.2013.07.052. Epub 2013 Aug 6.

Supplemental Content

Loading ...
Support Center